CompletedNot Applicable

Levosimendan Administration in Pulmonary Hypertension

Greece45 participantsStarted 2020-10-17

Plain-language summary

The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right ventricular function.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with pulmonary hypertension due to left ventricular dysfunction based on echocardiographic diagnosis preoperatively * elective cardiac surgery Exclusion Criteria: * primary pulmonary hypertension * thromboembolic disease * chronic obstructive pulmonary disease * emergency surgery * redo surgery * inability to consent to the study

What they're measuring

change from baseline in mean pulmonary arterial pressure (MPAP)

Timeframe: 20 minutes after levosimendan administration, at the end of surgery and 2 hours after Intensive Care Unit (ICU) admission

Trial details

NCT IDNCT04599816

SponsorAretaieion University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-10-17

View on ClinicalTrials.gov More Hypertension, Pulmonary trials